Economic Burden of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D), Considering the Costs of Cardiovascular Hospitalization Events in Colombia
Author(s)
Claudia A. López-Cabra, MSc, Médica epidemióloga1, Ángela Daniela Rodríguez, MSc, Economist2, wilson Mayorga Mogollon, MSc, Economist2, Diana Smith Lopez, MSc, Economist2, Silvia Juliana Rey, Esp., Médica1, Laura Idrobo, Esp., Médica1, DIANA C. ACOSTA, Esp., Médica1, Diana Gutierrez, MD, Market Access1, Ruben D. Marrugo, MSc, Economist1;
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To estimate the economic burden of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D), considering the standard of care and the costs of cardiovascular events in Colombia
METHODS: From a social perspective, direct healthcare system (management of CKD and T2D considering hospitalization for cardiovascular events) and household costs were evaluated, also indirect costs using Disability-Adjusted Life Years (DALY) and average income per worker. Direct costs per patient/year were calculated using a macro-costing approach. Hospitalization costs for cardiovascular risk were weighted with the following probabilities (calculated using KDIGO 2024): (a) 24,84% for microalbuminuria, 42,1% for macroalbuminuria, and 94,67% for end-stage renal disease (ESRD) in hospitalization for heart failure (b) 33,71% for microalbuminuria, 44,56% for macroalbuminuria, and 59,08% for ESRD in non-fatal myocardial infarction and (c) 31,93% for microalbuminuria, 39,01% for macroalbuminuria, and 55,33% for ESRD in non-fatal stroke. These values were used to conduct a cost and DALYs simulation associated with disease progression using a Markov model, employing a transition matrix for a cohort of 1.000 patients aged 40 with T2D
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), total direct cost in 2024 US dollars per patient/year was: USD$2.133 for microalbuminuria, USD$3.300 for macroalbuminuria and USD$13.879 for ESRD. Total healthcare costs per patient/year were USD$2.100 for microalbuminuria, USD$2.848 for macroalbuminuria y USD$10.705 for ESRD, but those related only to cardiovascular hospitalization were USD$1.987 for microalbuminuria, USD$2.735 for macroalbuminuria and USD$4.405 for ESRD. Out-of-pocket expenses were USD$33 for microalbuminuria, USD$452 for macroalbuminuria and USD$3.174 for ESRD per patient/year. Indirect costs were USD$526 for micro and macroalbuminuria, USD$2.888 for ESRD, and USD$5.059 for death stage, with a total of 10,6 DALYs per person
CONCLUSIONS: Economic burden of CKD in T2D associated with hospitalization for cardiovascular risk in Colombia is approximately USD$105.582 per patient in time horizon of 37 years
METHODS: From a social perspective, direct healthcare system (management of CKD and T2D considering hospitalization for cardiovascular events) and household costs were evaluated, also indirect costs using Disability-Adjusted Life Years (DALY) and average income per worker. Direct costs per patient/year were calculated using a macro-costing approach. Hospitalization costs for cardiovascular risk were weighted with the following probabilities (calculated using KDIGO 2024): (a) 24,84% for microalbuminuria, 42,1% for macroalbuminuria, and 94,67% for end-stage renal disease (ESRD) in hospitalization for heart failure (b) 33,71% for microalbuminuria, 44,56% for macroalbuminuria, and 59,08% for ESRD in non-fatal myocardial infarction and (c) 31,93% for microalbuminuria, 39,01% for macroalbuminuria, and 55,33% for ESRD in non-fatal stroke. These values were used to conduct a cost and DALYs simulation associated with disease progression using a Markov model, employing a transition matrix for a cohort of 1.000 patients aged 40 with T2D
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), total direct cost in 2024 US dollars per patient/year was: USD$2.133 for microalbuminuria, USD$3.300 for macroalbuminuria and USD$13.879 for ESRD. Total healthcare costs per patient/year were USD$2.100 for microalbuminuria, USD$2.848 for macroalbuminuria y USD$10.705 for ESRD, but those related only to cardiovascular hospitalization were USD$1.987 for microalbuminuria, USD$2.735 for macroalbuminuria and USD$4.405 for ESRD. Out-of-pocket expenses were USD$33 for microalbuminuria, USD$452 for macroalbuminuria and USD$3.174 for ESRD per patient/year. Indirect costs were USD$526 for micro and macroalbuminuria, USD$2.888 for ESRD, and USD$5.059 for death stage, with a total of 10,6 DALYs per person
CONCLUSIONS: Economic burden of CKD in T2D associated with hospitalization for cardiovascular risk in Colombia is approximately USD$105.582 per patient in time horizon of 37 years
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE126
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders